Did the FDA approve BPC-157 in 2026?

No. In July 2026 an FDA advisory committee recommended that BPC-157 be added to the Section 503A Bulk Drug Substances List. That is not FDA approval of BPC-157 as a drug, and the vote did not immediately make BPC-157 legal to compound.

What the committee actually voted on

On July 23–24, 2026, the FDA's Pharmacy Compounding Advisory Committee (PCAC) reviewed whether seven peptide substances should be eligible as ingredients when a licensed 503A pharmacy prepares a medication for an individual patient with a valid prescription. The BPC-157 vote was 8 yes, 6 no, 1 abstention — a recommendation, not an approval.

FDA approval of a drug normally requires controlled clinical trials, a defined dose, a standardized manufacturing process, a reviewed safety profile, and approved prescribing information. None of that happened here.

What the evidence shows

FDA evaluated BPC-157 in the context of ulcerative colitis. Most positive findings are preclinical — laboratory or animal research. FDA's review concluded the available information did not adequately establish effectiveness and raised concerns about product characterization, impurities, aggregation, and possible immune reactions.

There is no FDA-approved dose or established treatment protocol for BPC-157. Competitive athletes should also note that BPC-157 is prohibited under the World Anti-Doping Agency's S0 category for unapproved substances.

What patients should do

Do not start, stop, or change a treatment because of a headline about this vote, and do not inject a product labeled "research use only" or "not for human consumption." If you are already using a peptide, tell your physician what you are taking and bring the vial or a clear photo of the label.

Medically reviewed by Dr. Michael Mimlitz, MD (NPI 1508891870), Chief Physician of GOAL.MD. Physician-supervised telehealth. More at goal.md/answers.